Accretive Health (NYSE: AH ) reported earnings yesterday. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Accretive Health beat expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP earnings per share grew.
Gross margins dropped, operating margins increased, and net margins increased.
Accretive Health reported revenue of $253.7 million. The eight analysts polled by S&P Capital IQ wanted to see a top line of $231.8 million on the same basis. GAAP reported sales were 55% higher than the prior-year quarter's $163.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.06. The eight earnings estimates compiled by S&P Capital IQ predicted $0.06 per share. GAAP EPS of $0.01 for Q1 were much higher than the prior-year quarter's $0.00 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 17.6%, 330 basis points worse than the prior-year quarter. Operating margin was 0.9%, 70 basis points better than the prior-year quarter. Net margin was 0.6%, 50 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $236.4 million. On the bottom line, the average EPS estimate is $0.10.
Next year's average estimate for revenue is $989.1 million. The average EPS estimate is $0.44.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 28 members rating the stock outperform and seven members rating it underperform. Among five CAPS All-Star picks (recommendations by the highest-ranked CAPS members), three give Accretive Health a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Accretive Health is hold, with an average price target of $28.00.
Over the decades, small-cap stocks like Accretive Health have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.